


Supplementary Figure S9



Supplementary Fig. S9. Triplet therapy comprising CQ, Flt3L, and aLAG3 markedly suppresses tumor growth

(A) KPC1 cells were orthotopically transplanted into female C57BL/6 mice. Tumor-bearing mice were treated with vehicle, aLAG3 (50 μ g), CQ (60 mg/kg) + Flt3L (10 μ g), or CQ + Flt3L +aLAG3. After 21 days of treatment, the tumor volumes and weights were measured.

(B) KPC1 cells were orthotopically transplanted into male C57BL/6 mice. Tumor-bearing mice were treated with vehicle or CQ + Flt3L +aLAG3. After 28 days of treatment, the tumor volumes and weights were measured.

(C, D) Representative immunofluorescence images of cytotoxic CD8⁺ T cells, granzyme B⁺ CD8a⁺ T cells (CD8a [red] and granzyme B [green]) (B), and perforin⁺ CD8a⁺ T cells (CD8a [red] and

perforin [green]) (C). Quantification of granzyme B⁺ CD8a⁺ cells/DAPI⁺ cells (%) and granzyme B⁺ CD8a⁺ cells/CD8a⁺ cells (%) (B); and perforin⁺ CD8a⁺ cells/DAPI⁺ cells (%) and perforin⁺ CD8a⁺ cells/CD8a⁺ cells (%) (C) is shown.

(E) Treatment experiments were performed to compare the triple therapy (with Flt3L) and CQ+aLAG3 (without Flt3L) in orthotopic syngeneic PDAC tumors (KPC1).

Scale bars, 100 μ m (B and C). Bars, median; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, not significant; analyzed using the one-way ANOVA (A-D).